Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | DAO | P14920 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 8/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | HPD | P32754 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2632476 | 0.85 | POLB (0.40) | POLBDAOKDM4EGAAPGR | |
| SCHEMBL12730589 | 0.84 | PGR (0.46) | POLBDAOKDM4EGAAB3GNT2 | |
| SCHEMBL2632474 | 0.83 | POLB (0.41) | POLBDAOPGRHPD | |
| SCHEMBL1655471 | 0.72 | ATM (0.45) | POLBDAOKDM4EGAAPGR | |
| SCHEMBL10165987 | 0.72 | EZH2 (0.37) | POLBDAOKDM4EGAA | |
| SCHEMBL12793467 | 0.71 | DAO (0.42) | POLBDAOKDM4EGAAB3GNT2 | |
| SCHEMBL27295279 | 0.69 | POLB (0.68) | POLBKDM4EGAAB3GNT2PGR | |
| SCHEMBL31473364 | 0.69 | POLB (0.68) | POLBKDM4EGAAB3GNT2PGR | |
| SCHEMBL806063 | 0.68 | POLB (0.50) | POLBDAOPGRCYP3A4CYP2B6 | |
| SCHEMBL1656819 | 0.68 | POLB (0.50) | POLBDAOPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2012054874-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | POLB 399/4885DAO 2853/4885KDM4E 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.